Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574912 · ClinicalTrials.gov registry record · Phase 1
Characteristics of Glargine in Type 2 Diabetics
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00574912: Completed Phase 1 study, sponsored by Vanderbilt University Medical Center.
NCT00574912 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574912, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.
Primary Outcome
measuring the changes in glucose infusion rate during the 24 hour experimental period.
Interventions
- DRUG Placebo
- DRUG Insulin Glargine 0.5 u/kg body wt SC
- DRUG Insulin Glargine 1.0 u/kg body wt SC
- DRUG Insulin Glargine 1.5 u/kg body wt SC
- DRUG Insulin Glargine 2.0 u/kg body wt SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00574912 record still lists
NCT00574912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00574912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00574912 about?
NCT00574912 is a clinical study titled "Characteristics of Glargine in Type 2 Diabetics". The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes w...
What is the current status of trial NCT00574912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00574912?
The interventions under investigation include: Placebo (DRUG), Insulin Glargine 0.5 u/kg body wt SC (DRUG), Insulin Glargine 1.0 u/kg body wt SC (DRUG), Insulin Glargine 1.5 u/kg body wt SC (DRUG), Insulin Glargine 2.0 u/kg body wt SC (DRUG).
Who is sponsoring clinical trial NCT00574912?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00574912's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia